Saturday 17 October 2026
Export LGND’s income statement to Excel — free account
Ligand Pharmaceuticals Incorporated
LGND Healthcare Biotechnology
Ligand Pharmaceuticals Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $268.1 million, up 60.4% from fiscal 2024. In the quarter to June 2026, revenue grew 33.7%, EPS grew 868.0% and free cash flow grew 35.5%, each against the same quarter a year earlier.
295.54
2.96
−0.99%
Follow LGND
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
31.58 | 25.47 | 30.01 | 74.12 |
+8 more quarters Free account |
P/S ratio |
21.83 | 14.46 | 13.64 | 13.80 | |
P/FCF ratio |
44.23 | 29.50 | 60.02 | 136.42 | |
P/Operating CF |
264.04 | 81.53 | 79.63 | 264.94 | |
P/B ratio |
6.55 | 3.98 | 3.59 | 3.65 | |
Price to Tangible BV |
9.66 | 5.85 | 5.30 | 5.64 | |
EV/Sales |
21.25 | 13.49 | 12.77 | 13.19 | |
EV/EBITDA |
49.70 | 29.82 | 48.15 | 67.56 | |
EV/Operating CF |
46.88 | 29.98 | 69.35 | 103.82 | |
EV/FCF |
43.07 | 27.50 | 56.19 | 130.34 | |
Quick Ratio |
30.83 | 20.81 | 21.83 | 24.07 | |
Current Ratio |
31.18 | 21.28 | 22.23 | 24.69 | |
Net Debt/EBITDA |
(14.86) | (13.85) | (15.05) | (3.71) | |
Debt/Assets |
51.54% | 29.17% | 28.59% | 30.17% | |
Debt/Equity |
1.16 | 0.45 | 0.44 | 0.47 | |
Asset Turnover |
0.19 | 0.23 | 0.21 | 0.21 | |
Operating CF/Net income |
0.50 | (3.65) | 1.03 | 0.11 | |
Capex/Depreciation |
(0.02) | 0.90 | 0.03 | 0.13 | |
Interest Coverage |
4.91 | 9.94 | 7.76 | 60.36 | |
Research and Development Expense of Revenue |
23.03% | 4.15% | 5.88% | 18.20% | |
Selling, General and Administrative Expense of Revenue |
45.72% | 40.28% | 41.95% | 24.64% | |
Intangible Assets out of Total Assets |
0.14 | 0.21 | 0.21 | 0.23 | |
Share Based Compensation of Revenue |
21.44% | 20.49% | 23.92% | 12.77% | |
Graham Net Nets |
0.04 | 0.08 | 0.08 | 0.07 | |
Graham Number |
104.22 | 94.06 | 86.35 | 51.09 | |
Earnings Yield |
3.17% | 3.93% | 3.33% | 1.35% | |
Free Cash Flow Yield |
2.26% | 3.39% | 1.67% | 0.73% | |
Revenue per Share |
3.17 | 2.60 | 3.09 | 5.90 | |
Operating CF per Share |
1.20 | 2.45 | 2.37 | 0.67 | |
Capex per Share |
(0.01) | 0.34 | 0.01 | 0.05 | |
Free Cash Flow per Share |
1.19 | 2.79 | 2.38 | 0.72 | |
Cash per Share |
68.32 | 39.81 | 39.11 | 34.58 | |
Shareholders Equity per Share |
48.22 | 50.16 | 52.60 | 48.53 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
48.22 | 50.16 | 52.60 | 48.53 | |
Free Cash Flow |
23.87 | 55.44 | 46.12 | 14.08 | |
Working Capital |
1,410.38 | 824.75 | 794.82 | 723.38 | |
Capital Expenditures |
(0.14) | 6.75 | 0.20 | 0.99 | |
Net Current Asset Value |
238.76 | 330.63 | 288.85 | 227.32 | |
EV/EBIT |
65.18 | 39.14 | 83.48 | 189.10 | |
Capex to Sales |
0.00 | (0.13) | 0.00 | (0.01) | |
Price to Operating Income |
66.94 | 41.97 | 89.17 | 197.93 | |
| Other line items | |||||
Average Receivables |
61.16 | 48.81 | 51.75 | 50.11 | |
Average Payables |
8.99 | 5.32 | 4.24 | 4.19 | |
Average Inventory |
12.88 | 13.94 | 11.62 | 14.32 | |
Average Assets |
1,567.24 | 1,218.77 | 1,251.21 | 1,215.82 | |
Average Common Equity |
898.02 | 896.43 | 923.83 | 895.67 |
Columns are period end dates